US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ARIAD Pharmaceuticals

23.99

+0.0000

Volume:- -

Turnover:- -

Market Cap:4.66B

PE:-133.28

High:23.99

Open:23.99

Low:23.99

Close:23.99

Loading ...

Overview Company News Filings

ARIA Cybersecurity secures multi-year contract via Oryx partnership

ARIA Cybersecurity Secures Multiyear Contract to Protect Large South African Cell Tower Provider

ACCESS Newswire

Justin Sun listed the "Seven Deadly Sins" of FDT, including misuse of customer funds, fraud, and theft.

First Digital Statement: Did not participate in any coordination scheme or fund misappropriation, executed the transaction as per the instructions of Techteryx and its authorized representative

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

LGVN Announces Positive Alzheimer’s News

Zacks Small Cap Research

Press Release: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

ARIA Cybersecurity Partners with Oryx Industries to Protect Their Customers Critical Infrastructure Endpoints from Dangerous Cyberattacks

ACCESS Newswire

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

ARIA Cybersecurity Partners with Rexel to Protect Rockwell Automation Customers from Dangerous Cyberattacks

ACCESS Newswire

BrainBox AI's Cloud Building Management System and Award-Winning AI Agent ARIA Unite at AHR 2025

ACCESS Newswire

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

ProMIS Neurosciences Issues Letter to Shareholders

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

ARIA Cybersecurity enters reseller partnership with UFT

ARIA Cybersecurity Solutions Partners with UFT to Protect Water Treatment Facilities from Dangerous Cyberattacks

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ARIA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARIA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","market":"US","secType":"STK","nameCN":"ARIAD Pharmaceuticals","latestPrice":23.99,"timestamp":1745265600000,"preClose":23.99,"halted":0,"volume":0,"delay":0,"floatShares":169700000,"shares":194200862,"eps":-0.18,"marketStatus":"Pre-Mkt","change":0,"latestTime":"04-22 07:27:15 EDT","open":23.99,"high":23.99,"low":23.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.18,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":23.99,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARIA\",,,,,undefined,":{"symbol":"ARIA","floatShares":169700000,"roa":"--","roe":"--","lyrEps":0,"shares":194200862,"dividePrice":0,"high":23.99,"amplitude":0,"preClose":23.99,"low":23.99,"week52Low":23.99,"pbRate":"-100.52","week52High":23.99,"institutionHeld":0.5771,"latestPrice":23.99,"eps":-0.18,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.18,"open":23.99,"prevYearClose":23.99,"prevWeekClose":23.99,"prevMonthClose":23.99,"prevQuarterClose":23.99,"fiveDayClose":23.99,"twentyDayClose":23.99,"sixtyDayClose":23.99},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARIA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525894549","title":"ARIA Cybersecurity secures multi-year contract via Oryx partnership","url":"https://stock-news.laohu8.com/highlight/detail?id=2525894549","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525894549?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115421,"startTime":"0","endTime":"0","summary":"ARIA Cybersecurity announced a new contract via its new reseller partnership with Oryx to deploy ARIA’s flagship solution, AZT PROTECT, to protect ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aria-cybersecurity-secures-multi-year-contract-via-oryx-partnership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aria-cybersecurity-secures-multi-year-contract-via-oryx-partnership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARIA"],"gpt_icon":0},{"id":"2525915448","title":"ARIA Cybersecurity Secures Multiyear Contract to Protect Large South African Cell Tower Provider","url":"https://stock-news.laohu8.com/highlight/detail?id=2525915448","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525915448?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"ARIA AZT PROTECT to stop cyberattacks targeting 1000s of cell tower sites. BOSTON, MA / ACCESS Newswire / April 8, 2025 / ARIA Cybersecurity, a CSPi business  and a leading provider of cybersecurity solutions announced a new contract via its new reseller partnership with Oryx to deploy ARIA's flagship solution, AZT PROTECT, to protect equipment at one of the largest cell tower owners in South Africa.ARIA Cybersecurity, a business of CSPi Inc. , recognizes that better, stronger, more effective cybersecurity starts with a smarter approach. Our solutions provide new ways for organizations to protect their most critical assets-they can shield their critical applications from attack with our AZT PROTECT solution, while monitoring internal traffic, device-level logs, and alert output with our ARIA ADR solution to substantially improve threat detection and surgically disrupt cyberattacks and data exfiltration. Customers in a range of industries rely on our solutions to accelerate incident res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aria-cybersecurity-secures-multiyear-contract-120000618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSPI","ARIA","BK4134"],"gpt_icon":0},{"id":"2525962378","title":"Justin Sun listed the \"Seven Deadly Sins\" of FDT, including misuse of customer funds, fraud, and theft.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525962378","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525962378?lang=en_us&edition=fundamental","pubTime":"2025-04-08 19:48","pubTimestamp":1744112880,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 8th, Justin Sun posted on X platform listing the Seven Deadly Sins of First Digital Trust (FDT) as follows:· Sin #1: Breach of Trustee DutyUnder the Hong Kong Trustee Ordinance ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/288816","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK7095","ARIA","AML.AU","FDT","BK7504"],"gpt_icon":0},{"id":"2524287295","title":"First Digital Statement: Did not participate in any coordination scheme or fund misappropriation, executed the transaction as per the instructions of Techteryx and its authorized representative","url":"https://stock-news.laohu8.com/highlight/detail?id=2524287295","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524287295?lang=en_us&edition=fundamental","pubTime":"2025-04-03 16:57","pubTimestamp":1743670620,"startTime":"0","endTime":"0","summary":"BlockBeats News, April 3rd, First Digital released an official statement on social media platform: \"Today, Justin Sun's accusations against FDT at the press conference are baseless. We categorically d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/288148","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["ARIA","AML.AU","FDT","BK7504","BK7095"],"gpt_icon":0},{"id":"2524618914","title":"Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2524618914","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524618914?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:00","pubTimestamp":1743591600,"startTime":"0","endTime":"0","summary":"- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 -- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease  -. WATERTOWN, Mass., April 02, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting its oral small molecule program, including its lead clinical candidate VG-3927, in two oral presentations at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases being held April 1 – April 5 in Vienna, Austria.Oral presentation by Christian Mirescu, Ph.D., Senior Vice President, Neuroimmunology: Small Molecule TREM2 Agonists as Next-Generation Therapeutics for Alzheimer’s DiseaseDate and Time: Wednesday, April 2, 2025, 3:20 PM – 3:35 PM Session: TREM2, Microglia: From Mechanisms to Potenti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neuroscience-presents-data-small-110000638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4563","PAM","ARIA","BK4181","BK4213","CET","LU1169590202.USD","BK4218","PD","CSF","BK4139","VIGL","BK4081","VG","BK4023","LU1169589451.USD"],"gpt_icon":0},{"id":"2520451633","title":"Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2520451633","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520451633?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:00","pubTimestamp":1742475600,"startTime":"0","endTime":"0","summary":"Nataliya Agafonova, M.D., Chief Medical Officer, Longeveron","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046277/0/en/Longeveron-Announces-Positive-Type-B-Meeting-with-U-S-FDA-Regarding-Pathway-to-BLA-for-Laromestrocel-Lomecel-BTM-in-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","BK4139","MSC","BK4137","BTM","BK4575","BK4150","LGVN","AAIC","ARIA"],"gpt_icon":0},{"id":"2520234465","title":"LGVN Announces Positive Alzheimer’s News","url":"https://stock-news.laohu8.com/highlight/detail?id=2520234465","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520234465?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:05","pubTimestamp":1742468700,"startTime":"0","endTime":"0","summary":"Longeveron  is a company that should be getting more attention from investors and the just released annual results again proved that point. LGVN has made substantial progress with its signature treatment, Lomecel-B, in treating both HLHS and Alzheimer's Disease and we suggest investors take a look at this stock before more good news comes out—such as what happened recently.We continue to believe that Longeveron is an exciting clinical-stage company and investors aren’t appropriately appreciating the game-changing potential Lomecel-B may be able to have on multiple serious medical conditions. As a result of the prudent decisions made by management, we believe Lomecel-B will ulti","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lgvn-announces-positive-alzheimer-news-110500532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INN","LGVN","BK4181","BK4218","ARIA","BK4139"],"gpt_icon":0},{"id":"2519887682","title":"Press Release: AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519887682","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519887682?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:00","pubTimestamp":1741863600,"startTime":"0","endTime":"0","summary":"-- Landmark exclusive option and license deal with Takeda for ACI-24.060. with $100 million upfront and additional potential milestones of up to. about $2.1 billion plus royalties on sales upon commercialization. -- ACI-24.060 ABATE Phase 1b/2 trial showed encouraging interim safety and. tolerability data in Down syndrome  cohort; further interim results. in Alzheimer's disease  and DS expected in 2025. -- Enrollment progress in JNJ-2056  ReTain Phase 2b trial in. preclinical AD patients triggered second milestone payment of CHF 24.6. -- ACI-7104.056 VacSYn Phase 2 trial demonstrated positive interim safety. and immunogenicity results in Parkinson's disease ; further interim. \"The ability to innovate is key to our future success. Driven by our two drug discovery platforms, in 2024, we advanced multiple early-stage asse","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNV92.GBP","IE00BSNM7G36.USD","BK4581","IE00B42XCP33.USD","BK4007","LU0345769128.USD","LU1221951129.SGD","ARIA","LU1244550494.USD","LU2430703095.HKD","LU0114720955.EUR","BK4555","LU0203345920.USD","LU2089984988.USD","LU0234570918.USD","TM","LU0792757196.USD","03160","R","IE00B2B36J28.USD","JNJ","LU0234572021.USD","CBD","BK4604","ACIU","LU1059921491.USD","IE000M9KFDE8.USD","LU2505996509.AUD","PD","ACI","LU1778281490.HKD","LU1506573853.SGD","AC","IE0009355771.USD","IE00BDGV0183.EUR","SG9999002224.SGD","PET","LU0912757837.SGD","LU1032466523.USD","PSP","LU1162221912.USD","LU0320765646.SGD","LU0640476718.USD","AAIC","BK4532","LU1169589451.USD","IE00B4R5TH58.HKD","LU0098860793.USD","BK4592","LU1244550577.SGD"],"gpt_icon":0},{"id":"2518459727","title":"Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2518459727","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518459727?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:30","pubTimestamp":1741696200,"startTime":"0","endTime":"0","summary":"Joshua Hare, MD, FACC, FAHA, Co-Founder, Chief Science Officer and Chairman, Longeveron","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3040564/0/en/Longeveron-Announces-Nature-Medicine-Publication-of-Results-of-Phase-2a-Clinical-Trial-Evaluating-Laromestrocel-Lomecel-B-in-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PET","BK4139","BK4150","MSC","INN","BK4575","BK4192","BK4181","LGVN","BK4218","ARIA"],"gpt_icon":0},{"id":"2517943689","title":"ARIA Cybersecurity Partners with Oryx Industries to Protect Their Customers Critical Infrastructure Endpoints from Dangerous Cyberattacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2517943689","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517943689?lang=en_us&edition=fundamental","pubTime":"2025-03-05 22:40","pubTimestamp":1741185600,"startTime":"0","endTime":"0","summary":"Strategic Collaboration Brings Cutting-Edge Cybersecurity to Operational Technology Environments. LOWELL, MA / ACCESS Newswire / March 5, 2025 / Oryx Industries, a leading provider of trailblazing cybersecurity solutions, has announced a strategic partnership with ARIA Cybersecurity, a CSPi business , integrating the ARIA Zero Trust PROTECT  solution into its award-winning security portfolio. This collaboration brings an AI-driven, critical infrastructure solution to South African businesses and organizations who are looking to protect all Operational Technology  endpoints from both known and unknown cyber threats.\"Traditional security solutions are no longer enough to safeguard industrial control systems and OT environments from today's cyber threats,\" said Pranavan Chetty, Leadership Team, Oryx Industries. \"By partnering with ARIA Cybersecurity, we are equipping our clients with an AI-powered, proactive defense system that doesn't just detect threats-it stops them before they cause d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aria-cybersecurity-partners-oryx-industries-144000568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","ARIA","CSPI","CUBI","BK4134"],"gpt_icon":0},{"id":"2514382893","title":"Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382893","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514382893?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:05","pubTimestamp":1740603900,"startTime":"0","endTime":"0","summary":"Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK4527","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/26/3033325/0/en/Alector-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","PD","LU1169590202.USD","ARIA","LU1169589451.USD"],"gpt_icon":0},{"id":"2514370768","title":"ARIA Cybersecurity Partners with Rexel to Protect Rockwell Automation Customers from Dangerous Cyberattacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2514370768","media":"ACCESS Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514370768?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:00","pubTimestamp":1740574800,"startTime":"0","endTime":"0","summary":"Rexel adopts ARIA AZT PROTECT to stop cyberattacks targeting critical industrial infrastructure, completes deployment at first customer site in just one hour. LOWELL, MA / ACCESS Newswire / February 26, 2025 / ARIA Cybersecurity, a CSPi business  and a leading provider of cybersecurity solutions announced a new reseller partnership with Rexel USA, an industry leader in supplying industrial equipment throughout the United States. Rexel provides a variety of products to industrial customers across the U.S. and is a premier Rockwell Automation distributor.ARIA Cybersecurity, a business of CSPi Inc. , recognizes that better, stronger, more effective cybersecurity starts with a smarter approach. Our solutions provide new ways for organizations to protect their most critical assets-they can shield their critical applications from attack with our AZT solution, while monitoring internal traffic, device-level logs, and alert output with our ARIA ADR solution to substantially improve threat dete","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aria-cybersecurity-partners-rexel-protect-130000106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1894683264.USD","BK4585","ARIA","LU0154245673.USD","LU0689626769.HKD","BK4211","LU0154245756.USD","CUBI","BK4588","LU0390134368.USD","LU0124676726.USD","BK4134","BK4580","ROK","CSPI","BK4096","LU1894683348.USD"],"gpt_icon":0},{"id":"2510576038","title":"BrainBox AI's Cloud Building Management System and Award-Winning AI Agent ARIA Unite at AHR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510576038","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510576038?lang=en_us&edition=fundamental","pubTime":"2025-02-10 21:30","pubTimestamp":1739194200,"startTime":"0","endTime":"0","summary":"MONTREAL, QC / ACCESS Newswire / February 10, 2025 / BrainBox AI, a pioneer in autonomous and generative AI building technology, is offering attendees an exclusive experience with its Cloud Building Management System . The platform focuses on centralizing building management, offering a single-pane view for monitoring all sites, reducing oversight time.About BrainBox AIFounded in 2017, BrainBox AI was created to address the dilemma currently facing the built environment: its energy consumption and significant contribution to climate change. As innovators of the global energy transition, BrainBox AI's game-changing HVAC technology leverages autonomous AI to make buildings smarter, greener and more efficient. Working together with our trusted global partners, BrainBox AI supports real estate clients in various sectors, including office buildings, hotels, commercial retail, grocery stores, airp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brainbox-ais-cloud-building-management-133000880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0004086264.USD","BK4588","LU0323239441.USD","BK4504","IE00BGHQF417.EUR","TT","BK4225","LU2552382132.HKD","IE00BKVL7J92.USD","LU2211814178.USD","LU0238689110.USD","LU2089279066.USD","BK4533","BK4086","LU2229751404.USD","IE00B3CCJ633.GBP","LU0154245756.USD","LU2552382215.SGD","ARIA","LU2133065610.SGD","LU2211817866.USD","LU0154245673.USD","IE00B2PGVK34.USD","IE00BZ1G4Q59.USD","LU0323240290.USD","AHR","IE0004091025.USD","LU2552382058.USD","BK4585"],"gpt_icon":0},{"id":"2505094867","title":"Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2505094867","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505094867?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633600,"startTime":"0","endTime":"0","summary":"- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease  -. - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement –。WATERTOWN, Mass., Jan. 23, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of AD. Collectively, the safety, tolerability, pharmacokinetic , and pharmacodynamic  profile supports the advancement of VG-3927 into a Phase 2 clinical trial as a potential once-daily oral therapy for AD.Achieved robust and dose-dependent reduction of sTREM2 of up to approximately 50% in the cerebral spinal fluid  demonstrating a strong PK/PD relationship, sustained target engagement ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neuroscience-reports-positive-data-120000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4081","PAM","PD","PK","BK4218","BK4181","BK4023","BK4563","VIGL","CSF","LU1169589451.USD","ARIA","LU1169590202.USD","VG","BK4139"],"gpt_icon":0},{"id":"2503816715","title":"ProMIS Neurosciences Issues Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2503816715","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503816715?lang=en_us&edition=fundamental","pubTime":"2025-01-13 23:30","pubTimestamp":1736782200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Massachusetts, Jan.  13, 2025  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of anti","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008682/0/en/ProMIS-Neurosciences-Issues-Letter-to-Shareholders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARIA","LU0728928796.USD","LU1923622291.USD","LU2125909759.SGD","LU1815336091.USD","LU2125909916.SGD","MSA","BK4143","LU0053671581.USD","LU0757428866.USD"],"gpt_icon":0},{"id":"2503309098","title":"Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503309098","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503309098?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company’s commitment to developing genetically-validated th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008414/0/en/Alector-Reports-on-Recent-Progress-and-Outlines-Strategic-Priorities-for-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","LU1169589451.USD","PD","ARIA","LU1169590202.USD","PRGS","BK4023","BK4097"],"gpt_icon":0},{"id":"2502852331","title":"ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2502852331","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502852331?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":"Targeting toxic oligomers without binding to plaque, designed to reduce the risk of ARIA and potentially deliver enhanced outcomes for patientsCAMBRIDGE, Massachusetts, Jan.  10, 2025  (GLOBE NEWSWIRE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/10/3007552/0/en/ProMIS-Neurosciences-Initiates-Phase-1b-Clinical-Trial-PRECISE-AD-in-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PK","BK4181","MSA","ARIA","LU1923622291.USD","MCI","BK4218","LU0757428866.USD","LU0053671581.USD","LU2125909759.SGD","LU0728928796.USD","LU1815336091.USD","BK4143","LU2125909916.SGD"],"gpt_icon":0},{"id":"2502011140","title":"Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2502011140","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502011140?lang=en_us&edition=fundamental","pubTime":"2025-01-09 21:00","pubTimestamp":1736427600,"startTime":"0","endTime":"0","summary":"Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug dem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/09/3007016/0/en/Acumen-Pharmaceuticals-Announces-Journal-of-Prevention-of-Alzheimer-s-Disease-Publication-of-the-Company-s-Phase-1-INTERCEPT-AD-Study-Including-Target-Engagement-Dosing-Regimen-and.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PK","BK4181","BK4539","BK4218","ARIA","ABOS"],"gpt_icon":0},{"id":"2493750152","title":"ARIA Cybersecurity enters reseller partnership with UFT","url":"https://stock-news.laohu8.com/highlight/detail?id=2493750152","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493750152?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:30","pubTimestamp":1734960622,"startTime":"0","endTime":"0","summary":"ARIA Cybersecurity Solutions announced a new reseller partnership with United Flow Technologies. UFT provides products and system integration servi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aria-cybersecurity-enters-reseller-partnership-with-uft?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aria-cybersecurity-enters-reseller-partnership-with-uft?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARIA"],"gpt_icon":0},{"id":"2493765823","title":"ARIA Cybersecurity Solutions Partners with UFT to Protect Water Treatment Facilities from Dangerous Cyberattacks","url":"https://stock-news.laohu8.com/highlight/detail?id=2493765823","media":"ACCESSWIRE","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493765823?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:00","pubTimestamp":1734958800,"startTime":"0","endTime":"0","summary":"UFT to Resell ARIA AZT PROTECT to stop cyberattacks targeting Water Treatment and Wastewater facilities throughout North America. BOSTON, MA / ACCESSWIRE / December 23, 2024 / ARIA Cybersecurity Solutions, a CSPi business  a leading provider of cybersecurity solutions announced a new reseller partnership with United Flow Technologies  the industry leader in providing equipment and services to the water treatment industry.UFT provides products and system integration services to water and wastewater treatment facilities across 40 US states.ARIA's AZT PROTECT zero trust solution provides a lock-down approach to protecting critical infrastructure applications from attack, focusing on stopping all forms of malware, ransomware as well as nation-state-backed attacks on these applications and the OS on which they run.Water treatment has been hit hard by zero-day malware and ransomware that today's cybersecurity solutions struggle to stop. On top of that, Nation-state-sponsored attacks are focu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aria-cybersecurity-solutions-partners-uft-130000394.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4134","ARIA","CSPI"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":31,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARIA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2016-11-07","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.19,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1478494800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-07-28","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1469678400000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-05-10","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1462852800000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2016-02-23","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1456203600000,"reportTimeType":"pre","actualEps":-0.32},{"market":"US","date":"2015-11-03","symbol":"ARIA","fiscalQuarterEnding":null,"expectedEps":-0.2,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1446526800000,"reportTimeType":"pre","actualEps":-0.29}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARIA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARIA\",market:\"US\",delay:false,,,undefined,":{}}}